Liu Yatian, Wang Xiaojun, Jiang Xuesong, Yan Pengwei, Zhan Liangliang, Zhu Huanfeng, Wang Tingting, Wen Jing
Department of Radiotherapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Department of Thoracic Surgery, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
J Cell Biochem. 2019 May;120(5):7845-7857. doi: 10.1002/jcb.28059. Epub 2018 Nov 13.
Aberrant microRNAs (miRNAs) expressions could contribute to the progression of numerous cancers, including esophageal squamous cell carcinoma, while miR-10a participates in multiple biological processes on cancers. However, the molecular mechanism of miR-10a in esophageal squamous cell carcinoma (ESCC) has not been investigated. Herein, miR-10a was significantly reduced in ESCC clinical tissues and ESCC cell lines (EC109 and TE-3). In addition, immunohistochemistry indicated that the expressions of α-SMA, Ki-67, and PCNA in tumor tissues were higher than that of controls. In vitro, overexpression of miR-10a dramatically suppressed cell proliferation and enhanced cell apoptosis, while the decrease of miR-10a expressed the opposite outcome. Specially, overexpression of miR-10a caused a G0/G1 peak accumulation. Moreover, miR-10a also negatively regulated ESCC cell migration and invasion. Furthermore, targetscan bioinformatics predictions and the dual-luciferase assay confirmed that Tiam1 was a direct target gene of miR-10a. The statistical analysis showed Tiam1 was negatively in correlation with miR-10a in ESCC patient samples. And silencing Tiam1 could lead to a decline on cell growth, invasion, and migration in ESCC cell lines, while it could enhance cell apoptosis and cause a G0/G1 peak accumulation. In vivo, it revealed that miR-10a notably decreased the tumor growth and metastasis in xenograft model and pulmonary metastasis model. And it showed a lower expressions of Tiam1 in the miR-10a mimics group by immunohistochemistry. Taken together the results, they indicated that miR-10a might function as a novel tumor suppressor in vitro and in vivo via targeting Tiam1, suggesting miR-10a to be a candidate biomarker for the ESCC therapy.
异常的微小RNA(miRNA)表达可能促进包括食管鳞状细胞癌在内的多种癌症的进展,而miR-10a参与癌症的多个生物学过程。然而,miR-10a在食管鳞状细胞癌(ESCC)中的分子机制尚未得到研究。在此,miR-10a在ESCC临床组织和ESCC细胞系(EC109和TE-3)中显著降低。此外,免疫组织化学表明肿瘤组织中α-SMA、Ki-67和PCNA的表达高于对照组。在体外,miR-10a的过表达显著抑制细胞增殖并增强细胞凋亡,而miR-10a表达降低则产生相反的结果。特别地,miR-10a的过表达导致G0/G1峰积累。此外,miR-10a还负向调节ESCC细胞的迁移和侵袭。此外,TargetScan生物信息学预测和双荧光素酶测定证实Tiam1是miR-10a的直接靶基因。统计分析表明,在ESCC患者样本中Tiam1与miR-10a呈负相关。沉默Tiam1可导致ESCC细胞系中细胞生长、侵袭和迁移下降,同时可增强细胞凋亡并导致G0/G1峰积累。在体内,结果显示miR-10a在异种移植模型和肺转移模型中显著降低肿瘤生长和转移。免疫组织化学显示miR-10a模拟物组中Tiam1的表达较低。综上所述,这些结果表明miR-10a可能通过靶向Tiam1在体外和体内发挥新型肿瘤抑制作用,提示miR-10a可能是ESCC治疗的候选生物标志物。